Biotech & Pharma.T.A, Message Board

Sponsor

To: Jibacoa who wrote (3107)	2/3/2012 11:02:52 AM
From: Jibacoa	Read Replies (1) of 3185

CYTX is among the few biotechs that have doubled in price so far this year.<g> It has received an IDE approval from the FDA to begin the ATHENA trial. <g>. ATHENA will investigate the use of the Celution System, to prepare adipose-derived stem and regenerative cells to treat chronic myocardial ischemia . (The IDE application was originally submitted to the FDA in December. ). The ATHENA plans to enroll 45 patients with CMI who have limited therapeutic options. It will evaluate a variety of clinical and functional outcomes, including safety, peak oxygen consumption and clinical outcomes at 12-months. CYTX insiders did a good amount of buying late last year and so far this year, seem to just be exercising their options.<g> However, the institutions sold abut 10% of their holdings late last year.<g> CYTX has been burning its cash at a good pace and has substantial LTD. It seems it will need some new cash infusion in the near future. <g> The ACTAY is $4.50 and last year H was $8.44 Next earnings report is expected on March 12. Volume has increased in the last two days and the stock looks overbought near-term as the price is getting too far from its EMA 5 and the RSI climbs above 80 <g> bigcharts.marketwatch.com Bernard